Trial Profile
A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pemrametostat (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 Feb 2022 Status changed from active, no longer recruiting to discontinued due to internal review of clinical data in context of indication under investigation.
- 21 Jan 2022 Planned End Date changed from 23 Apr 2025 to 31 Jan 2022.
- 21 Jan 2022 Planned primary completion date changed from 23 Apr 2025 to 31 Jan 2022.